NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Qayyum R, Wilson LM, Bolen S, et al. Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Sep. (Comparative Effectiveness Reviews, No. 14.)
This publication is provided for historical reference only and the information may be out of date.
MEDLINE Strategy
| Terms | Returns |
|---|---|
| ((“diabetes mellitus, type 2”[mh] OR “type 2 diabetes”[tiab] OR ((diabetes[tiab] OR diabetics[tiab] OR diabetic[tiab]) AND (“non-insulin dependent”[tiab] OR “type 2”[tiab] or type-2[tiab] OR “type II”[tiab]))) AND (“insulin/analogs and derivatives”[mh] OR “BIAsp 30”[tiab] OR “BIAsp30”[tiab] OR (Humalog[tiab] AND (Mix[tiab] OR 25[tiab] OR 50[tiab])) OR (NovoLog[tiab] AND (Mix[tiab] OR 70[tiab] OR 30[tiab])) OR (insulin[tiab] AND ((biphasic[tiab] OR premixed[tiab] OR “pre-mixed”[tiab] OR protamin*[tiab] OR Mix[tiab] OR mixture[tiab]) OR (aspart[tiab] OR lispro[tiab] OR analogue[tiab] OR analogues[tiab] OR analog[tiab] OR analogs[tiab] OR Humalog[tiab]))))) NOT (animals[mh]NOT humans[mh]) | 1149 |
EMBASE Strategy
| ((‘non insulin dependent diabetes mellitus’/exp OR ‘type 2 diabetes’:ti,ab OR ((diabetes:ti,ab OR diabetics:ti,ab OR diabetic:ti,ab) AND (‘non-insulin dependent’:ti,ab OR ‘type 2’:ti,ab or type-2:ti,ab OR ‘type II’:ti,ab))) AND (‘biphasic insulin’/exp OR ‘BIAsp 30’:ti,ab OR ‘BIAsp30’:ti,ab OR (Humalog:ti,ab AND (Mix:ti,ab OR 25:ti,ab OR 50:ti,ab)) OR (NovoLog:ti,ab AND (Mix:ti,ab OR 70:ti,ab OR 30:ti,ab)) OR ((insulin:ti,ab AND (biphasic:ti,ab OR premixed:ti,ab OR ‘pre-mixed’:ti,ab OR protamin*:ti,ab OR Mix:ti,ab) OR (aspart:ti,ab OR lispro:ti,ab OR analogue:ti,ab OR analogues:ti,ab OR analog:ti,ab OR analogs:ti,ab OR Humalog:ti,ab))))) NOT ([animals]/lim NOT [humans]/lim) | 1344 |
Cumulative Index to Nursing and Applied Health Literature (CINAHL)
| (((MH “Diabetes Mellitus, Non-Insulin-Dependent”) OR (TX “type 2 diabetes”) OR (((TX “diabetes”) OR (TX “diabetics”) OR (TX “diabetic”)) AND ((TX “non-insulin dependent”) OR (TX “type 2”) or (TX “type-2”) OR ( TX “type II”)))) AND ((MH “Insulin/AA”) OR (TX “BIAsp 30”) OR (TX “BIAsp30”) OR ((TX “Humalog”) AND ((TX “Mix”) OR (TX “25”) OR (TX “50”))) OR ((TX “NovoLog”) AND ((TX “Mix”) OR (TX “70”) OR (TX “30”))) OR ((TX “insulin”) AND (((TX “biphasic”) OR (TX “premixed”) OR (TX “pre-mixed”) OR (TX “protamin*”) OR (TX “Mix”) OR (TX “mixture”)) OR ((TX “aspart”) OR (TX “lispro”) OR (TX “analogue”) OR (TX “analogues”) OR (TX “analog”) OR (TX “analogs”) OR (TX “Humalog”)))))) | 299 |
The Cochrane Central Register of Controlled Trials (CENTRAL)
| #1 (type 2 diabetes):ti,ab,kw in Clinical Trials #2 (diabetes):ti,ab,kw or (diabetics):ti,ab,kw or (diabetic):ti,ab,kw in Clinical Trials #3 (non-insulin dependent):ti,ab,kw or (type 2):ti,ab,kw or (type-2):ti,ab,kw or (type II):ti,ab,kw in Clinical Trials #4 (#2 AND #3) #5 (#1 OR #4) #6 (BIAsp 30):ti,ab,kw or (BIAsp30):ti,ab,kw in Clinical Trials #7 (Humalog):ti,ab,kw in Clinical Trials #8 (Mix):ti,ab,kw or (25):ti,ab,kw or (50):ti,ab,kw in Clinical Trials #9 (#7 AND #8) #10 (NovoLog):ti,ab,kw in Clinical Trials #11 (Mix):ti,ab,kw or (70):ti,ab,kw or (30):ti,ab,kw in Clinical Trials #12 (#10 AND #11) #13 (insulin):ti,ab,kw in Clinical Trials #14 (biphasic):ti,ab,kw or (premixed):ti,ab,kw or (pre-mixed):ti,ab,kw or (protamin*):ti,ab,kw or (mix):ti,ab,kw in Clinical Trials #15 (mixture):ti,ab,kw in Clinical Trials #16 (#14 OR #15) #17 (aspart):ti,ab,kw or (lispro):ti,ab,kw or (analogue):ti,ab,kw or (analogues):ti,ab,kw or (analog):ti,ab,kw in Clinical Trials #18 (analogs):ti,ab,kw or (Humalog):ti,ab,kw in Clinical Trials #19 (#17 OR #18) #20 (#16 OR #19) #21 (#13 AND #20) #22 (#6 OR #9 OR #12 OR #21) #23 (#5 AND #22) | 654 |